Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *
                     Welcome to STN International
                 Web Page for STN Seminar Schedule - N. America
NEWS
NEWS
         MAR 31
                 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                 IPC display formats
NEWS
      3
         MAR 31
                 CAS REGISTRY enhanced with additional experimental
                 spectra
NEWS
         MAR 31
                 CA/CAplus and CASREACT patent number format for U.S.
                 applications updated
      5 MAR 31
                 LPCI now available as a replacement to LDPCI
NEWS
NEWS 6 MAR 31
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS
      7
         APR 04
                 STN AnaVist, Version 1, to be discontinued
NEWS 8 APR 15
                 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS 9 APR 28
                 EMBASE Controlled Term thesaurus enhanced
NEWS 10 APR 28
                 IMSRESEARCH reloaded with enhancements
NEWS 11 MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
NEWS 12 MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
NEWS 13
         JUN 06
                 EPFULL enhanced with 260,000 English abstracts
NEWS 14
         JUN 06
                 KOREAPAT updated with 41,000 documents
NEWS 15
         JUN 13
                 USPATFULL and USPAT2 updated with 11-character
                 patent numbers for U.S. applications
                 CAS REGISTRY includes selected substances from
NEWS 16
         JUN 19
                 web-based collections
NEWS 17
         JUN 25
                 CA/CAplus and USPAT databases updated with IPC
                 reclassification data
                 AEROSPACE enhanced with more than 1 million U.S.
NEWS 18
         JUN 30
                 patent records
                 EMBASE, EMBAL, and LEMBASE updated with additional
NEWS 19
         JUN 30
                 options to display authors and affiliated
                 organizations
NEWS 20
                 STN on the Web enhanced with new STN AnaVist
         JUN 30
                 Assistant and BLAST plug-in
         JUN 30
NEWS 21
                 STN AnaVist enhanced with database content from EPFULL
NEWS 22
         JUL 28
                 CA/CAplus patent coverage enhanced
NEWS 23
         JUL 28
                 EPFULL enhanced with additional legal status
                 information from the epoline Register
NEWS 24
         JUL 28
                 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25
         JUL 28
                 STN Viewer performance improved
                 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 26
         AUG 01
NEWS 27
         AUG 13 CA/CAplus enhanced with printed Chemical Abstracts
```

page images from 1967-1998

NEWS 28 AUG 15 CAOLD to be discontinued on December 31, 2008 NEWS 29 AUG 15 CAplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:02:48 ON 24 AUG 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE Do you want to switch to the Registry File? Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:03:03 ON 24 AUG 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2008 HIGHEST RN 1042980-87-9 DICTIONARY FILE UPDATES: 22 AUG 2008 HIGHEST RN 1042980-87-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10553957Z.str

```
chain nodes :
14 15 16 17 18 26 27 28 29 30 31 32
ring nodes :
1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 10 \quad 11 \quad 12 \quad 13 \quad 20 \quad 21 \quad 22 \quad 23 \quad 24 \quad 25
chain bonds :
5-18 11-14 14-15 15-16 16-17 16-30 17-29 21-31 22-26 26-27 27-28 28-29
31-32
ring bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-7 \quad 5-6 \quad 5-9 \quad 6-7 \quad 7-10 \quad 8-9 \quad 8-13 \quad 9-10 \quad 10-11 \quad 11-12 \quad 12-13
20-21 20-25 21-22 22-23 23-24 24-25
exact/norm bonds :
5-6 5-9 11-14 16-30 21-31 22-26
exact bonds :
5-18 7-10 14-15 15-16 16-17 17-29 26-27 27-28 28-29 31-32
normalized bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-7 \quad 6-7 \quad 8-9 \quad 8-13 \quad 9-10 \quad 10-11 \quad 11-12 \quad 12-13 \quad 20-21 \quad 20-25
21-22 22-23 23-24 24-25
isolated ring systems :
containing 1 : 20 :
```


Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10553957Z.str



chain nodes : 14 15 16 17 18 26 27 28 29 30 31 32 ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 20 21 22 23 24 25 chain bonds : 5-18 11-14 14-15 15-16 16-17 16-30 17-29 21-31 22-26 26-27 27-28 28-29 31-32 ring bonds : $1 - 2 \quad 1 - 6 \quad 2 - 3 \quad 3 - 4 \quad 4 - 7 \quad 5 - 6 \quad 5 - 9 \quad 6 - 7 \quad 7 - 10 \quad 8 - 9 \quad 8 - 13 \quad 9 - 10 \quad 10 - 11 \quad 11 - 12 \quad 12 - 13$ 20-21 20-25 21-22 22-23 23-24 24-25 exact/norm bonds : 5-6 5-9 11-14 16-30 21-31 22-26 exact bonds : 5-18 7-10 14-15 15-16 16-17 17-29 26-27 27-28 28-29 31-32normalized bonds : $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-7 \quad 6-7 \quad 8-9 \quad 8-13 \quad 9-10 \quad 10-11 \quad 11-12 \quad 12-13 \quad 20-21 \quad 20-25$ 21-22 22-23 23-24 24-25 isolated ring systems : containing 1 : 20 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

L2 STRUCTURE UPLOADED

=> D L1 L1 HAS NO ANSWERS L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 13:03:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 5 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 5 TO 234

L3 5 SEA SSS SAM L1

=> S L1 SSS FULL

FULL SEARCH INITIATED 13:03:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 310 TO ITERATE

100.0% PROCESSED 310 ITERATIONS 100 ANSWERS

SEARCH TIME: 00.00.01

L4 100 SEA SSS FUL L1

=> FIL HCAPLUS

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
178.82
179.03

FILE 'HCAPLUS' ENTERED AT 13:04:02 ON 24 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2008 VOL 149 ISS 9 FILE LAST UPDATED: 22 Aug 2008 (20080822/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L4

L5 1858 L4

=> S L5 AND PROCESS

2667765 PROCESS

1827488 PROCESSES

3981697 PROCESS

(PROCESS OR PROCESSES)

L6 131 L5 AND PROCESS

=> S L6 AND APROTIC ORGANIC SOLVENT

15954 APROTIC

8 APROTICS

15958 APROTIC

(APROTIC OR APROTICS)

419844 ORGANIC

4056 ORGANICS

422464 ORGANIC

(ORGANIC OR ORGANICS)

1091661 ORG

16932 ORGS

1097874 ORG

(ORG OR ORGS)

1217122 ORGANIC

(ORGANIC OR ORG)

750728 SOLVENT

360518 SOLVENTS

937246 SOLVENT

(SOLVENT OR SOLVENTS)

697 APROTIC ORGANIC SOLVENT

(APROTIC(W)ORGANIC(W)SOLVENT)

L7 1 L6 AND APROTIC ORGANIC SOLVENT

=> S L6 AND APROTIC SOLVENT 15954 APROTIC

```
8 APROTICS
         15958 APROTIC
                 (APROTIC OR APROTICS)
        750728 SOLVENT
        360518 SOLVENTS
        937246 SOLVENT
                 (SOLVENT OR SOLVENTS)
          9755 APROTIC SOLVENT
                 (APROTIC (W) SOLVENT)
L8
             1 L6 AND APROTIC SOLVENT
=> S L6 AND APROTIC
         15954 APROTIC
             8 APROTICS
         15958 APROTIC
                (APROTIC OR APROTICS)
L9
             2 L6 AND APROTIC
=> S L6 AND CATALYST
        812115 CATALYST
        808991 CATALYSTS
       1040133 CATALYST
                 (CATALYST OR CATALYSTS)
L10
             4 L6 AND CATALYST
=> S L10 AND APROTIC SOLVENT
         15954 APROTIC
             8 APROTICS
         15958 APROTIC
                (APROTIC OR APROTICS)
        750728 SOLVENT
        360518 SOLVENTS
        937246 SOLVENT
                 (SOLVENT OR SOLVENTS)
          9755 APROTIC SOLVENT
                 (APROTIC (W) SOLVENT)
L11
             0 L10 AND APROTIC SOLVENT
=> S L10 AND APROTIC
         15954 APROTIC
             8 APROTICS
         15958 APROTIC
                 (APROTIC OR APROTICS)
L12
             1 L10 AND APROTIC
=> D HIS
     (FILE 'HOME' ENTERED AT 13:02:48 ON 24 AUG 2008)
     FILE 'REGISTRY' ENTERED AT 13:03:03 ON 24 AUG 2008
L1
                STRUCTURE UPLOADED
L2
                STRUCTURE UPLOADED
L3
              5 S L1
L4
            100 S L1 SSS FULL
    FILE 'HCAPLUS' ENTERED AT 13:04:02 ON 24 AUG 2008
           1858 S L4
L_5
```

```
131 S L5 AND PROCESS
L6
             1 S L6 AND APROTIC ORGANIC SOLVENT
L7
L8
              1 S L6 AND APROTIC SOLVENT
              2 S L6 AND APROTIC
L9
L10
             4 S L6 AND CATALYST
             0 S L10 AND APROTIC SOLVENT
L11
             1 S L10 AND APROTIC
L12
=> S CARVEDILOL
          1971 CARVEDILOL
            1 CARVEDILOLS
L13
          1971 CARVEDILOL
                 (CARVEDILOL OR CARVEDILOLS)
=> S L13 AND PROCESS
       2667765 PROCESS
       1827488 PROCESSES
       3981697 PROCESS
                (PROCESS OR PROCESSES)
L14
           137 L13 AND PROCESS
=> S L14 AND APROTIC
         15954 APROTIC
             8 APROTICS
         15958 APROTIC
                (APROTIC OR APROTICS)
L15
             2 L14 AND APROTIC
=> S L14 AND APROTIC SOLVENT
         15954 APROTIC
             8 APROTICS
         15958 APROTIC
                 (APROTIC OR APROTICS)
        750728 SOLVENT
        360518 SOLVENTS
        937246 SOLVENT
                 (SOLVENT OR SOLVENTS)
          9755 APROTIC SOLVENT
                 (APROTIC (W) SOLVENT)
L16
             1 L14 AND APROTIC SOLVENT
=> S L13 AND PREPARATION
       1633955 PREPARATION
         84016 PREPARATIONS
       1713248 PREPARATION
                 (PREPARATION OR PREPARATIONS)
       2938131 PREPN
        214675 PREPNS
       3099577 PREPN
                 (PREPN OR PREPNS)
       3995297 PREPARATION
                 (PREPARATION OR PREPN)
L17
           207 L13 AND PREPARATION
=> S L17 AND APROTIC SOLVENT
         15954 APROTIC
             8 APROTICS
```

```
15958 APROTIC
               (APROTIC OR APROTICS)
       750728 SOLVENT
       360518 SOLVENTS
       937246 SOLVENT
                (SOLVENT OR SOLVENTS)
         9755 APROTIC SOLVENT
               (APROTIC(W)SOLVENT)
L18
            1 L17 AND APROTIC SOLVENT
=> D HIS
    (FILE 'HOME' ENTERED AT 13:02:48 ON 24 AUG 2008)
    FILE 'REGISTRY' ENTERED AT 13:03:03 ON 24 AUG 2008
              STRUCTURE UPLOADED
T.1
L2
               STRUCTURE UPLOADED
L3
             5 S L1
L4
           100 S L1 SSS FULL
    FILE 'HCAPLUS' ENTERED AT 13:04:02 ON 24 AUG 2008
L5
          1858 S L4
L6
           131 S L5 AND PROCESS
L7
             1 S L6 AND APROTIC ORGANIC SOLVENT
             1 S L6 AND APROTIC SOLVENT
L8
             2 S L6 AND APROTIC
L9
L10
            4 S L6 AND CATALYST
L11
            0 S L10 AND APROTIC SOLVENT
L12
            1 S L10 AND APROTIC
L13
         1971 S CARVEDILOL
L14
          137 S L13 AND PROCESS
L15
             2 S L14 AND APROTIC
L16
             1 S L14 AND APROTIC SOLVENT
L17
           207 S L13 AND PREPARATION
L18
            1 S L17 AND APROTIC SOLVENT
=> d 17 ibib abs hitstr tot
L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154673 HCAPLUS
DOCUMENT NUMBER:
                      142:93675
TITLE:
                      A process for preparation of
                       1-[9H-carbazol-4-yloxy]-3-[[2-(2-
                       methoxyphenoxy)ethyl]amino]propan-2-ol
                       Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;
INVENTOR(S):
                       Thennati, Rajamannar
                      Sun Pharmaceutical Industries Limited, India
PATENT ASSIGNEE(S):
                       PCT Int. Appl., 27 pp.
SOURCE:
                       CODEN: PIXXD2
DOCUMENT TYPE:
                       Patent
LANGUAGE:
                       English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
                      KIND DATE APPLICATION NO. DATE
    PATENT NO.
                      ----
                             -----
                                         _____
                       A1 20041229
                                        WO 2004-IN52
    WO 2004113296
                                                             20040304
```

```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
                                            IN 2003-MU647
     IN 2003MU00647
                         Α
                                20050211
                                                                  20030620
                                            US 2005-553957
     US 20060270858
                         Α1
                                20061130
                                                                  20051019
PRIORITY APPLN. INFO.:
                                            IN 2003-MU647
                                                               A 20030620
                                            IN 2003-MU721
                                                               A 20030717
                                                               W 20040304
                                           WO 2004-IN52
OTHER SOURCE(S): CASREACT 142:93675; MARPAT 142:93675
GT
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The present invention provides a process for preparation of AB 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 q (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g(0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9Hcarbazole were added and the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous

layer was separated, and the product enriched organic layer was washed with water

till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature $60-70\,^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystal from 3 vols. EtOAc to obtain carvedilol (42 g).

IT 72956-09-3P, Carvedilol 95093-99-5P,

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl) benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 95093-99-5 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 95094-00-1 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 ibib abs hitstr tot

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:38855 HCAPLUS

DOCUMENT NUMBER: 146:142505

TITLE: Process for preparation of carvedilol

INVENTOR(S): Kumar, Ashok; Saxena, Ashvini; Bhattacharyya, Anindya;

Singh Sengar, Amit Vikram; Pathak, Gunjan Pramod; Soudagar, Satish Rajanikant; Mathur, Pramil Kumar; Nijasure, Avinash Manohar; Salunke, Sanjukumar Motiram; Gautam, Prashant; Ramsingh, Thakur

Gajendrasingh; Jadhav, Dilip Uttam

PATENT ASSIGNEE(S): IPCA Laboratories Ltd., India

SOURCE: Eur. Pat. Appl., 11pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.						KIND DATE				APP1	LICAT	ION 1	NO.		D.	DATE				
							_														
	EP	1741	700			A1		2007	0110		EP 2	2006-	1167	52		2	0060	706			
		R:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	, ES,	FI,	FR,	GB,	GR,	HU,	IE,			
			IS,	ΙΤ,	LI,	LT,	LU,	LV,	MC,	NL,	PL,	, PT,	RO,	SE,	SI,	SK,	TR,	AL,			
			ΒA,	HR,	MK,	YU															
	IN	2005	0 0 UM	807		Α		2007	0629		IN 2	2005-1	08UM	7		2	0050	706			
	US	2007	0027	202		A1		2007	0201		US 2	2006-	4805	26		2	0060	705			
PRIO	RIT	APP	LN.	INFO	. :						IN 2	2005-	08UM	7		A 2	0050	706			

OTHER SOURCE(S): CASREACT 146:142505

AB Disclosed herein is a process for preparation of carvedilol free from impurity, which comprises reaction of 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine in a polar aprotic solvent, followed by isolation of carvedilol as an acid addition salt and subsequent conversion into pure carvedilol.

IT 918903-19-2P 918903-21-6P 918903-23-8P 918903-28-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of carvedilol)

RN 918903-19-2 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, 4-methylbenzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

CM 2

CRN 104-15-4 CMF C7 H8 O3 S

918903-21-6 HCAPLUS 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-,sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

MeO

CM 2

CRN 7664-93-9 CMF H2 O4 S

о но-s-он |

RN 918903-23-8 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, acetate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

MeO

CM 2

CRN 64-19-7 CMF C2 H4 O2

RN 918903-28-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, phosphate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

MeO

CM 2

CRN 7664-38-2 CMF H3 O4 P

IT 72956-09-3P, Carvedilol

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carvedilol)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 19 ibib abs hitstr tot

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:38855 HCAPLUS

DOCUMENT NUMBER: 146:142505

TITLE: Process for preparation of carvedilol

INVENTOR(S): Kumar, Ashok; Saxena, Ashvini; Bhattacharyya, Anindya;

Singh Sengar, Amit Vikram; Pathak, Gunjan Pramod; Soudagar, Satish Rajanikant; Mathur, Pramil Kumar; Nijasure, Avinash Manohar; Salunke, Sanjukumar Motiram; Gautam, Prashant; Ramsingh, Thakur

Gajendrasingh; Jadhav, Dilip Uttam

PATENT ASSIGNEE(S): IPCA Laboratories Ltd., India

SOURCE: Eur. Pat. Appl., 11pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KI	ND DATE		APPLICATION NO. DATE								
EP 1741700	Αí	L 2007	0110	EP 2	2006-	1167	52		2	0060	706	
R: AT, BE,	BG, CH,	CY, CZ,	DE,	DK, EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,	
IS, IT,	LI, LT,	LU, LV,	MC,	NL, PL,	PT,	RO,	SE,	SI,	SK,	TR,	AL,	
BA, HR,	MK, YU											
IN 2005MU00807	А		0629	IN 2	2005-1	MU80.	7		2	0050	706	
US 20070027202	A2	1 2007	0201	US 2	2006-	48052	26		2	0060	705	
PRIORITY APPLN. INFO.	:			IN 2	2005-1	MU80'	7	Ž	A 2	0050	706	

OTHER SOURCE(S): CASREACT 146:142505

AB Disclosed herein is a process for preparation of carvedilol free from impurity, which comprises reaction of 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine in a polar aprotic solvent, followed by isolation of carvedilol as an acid addition salt and subsequent conversion into pure carvedilol.

IT 918903-19-2P 918903-21-6P 918903-23-8P

918903-28-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of carvedilol)

RN 918903-19-2 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, 4-methylbenzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

CM 2

CRN 104-15-4 CMF C7 H8 O3 S

918903-21-6 HCAPLUS 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-,sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

CM 2

CRN 7664-93-9 CMF H2 O4 S

RN 918903-23-8 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, acetate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

MeO

CM 2

CRN 64-19-7 CMF C2 H4 O2

RN 918903-28-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, phosphate (1:?) (CA INDEX NAME)

CM 1

CRN 72956-09-3 CMF C24 H26 N2 O4

PAGE 1-A

PAGE 2-A

MeO

CM 2

CRN 7664-38-2 CMF H3 O4 P

IT 72956-09-3P, Carvedilol

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carvedilol)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-

methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.						DATE		APPLICATION NO. DATE								
WC	2004	1132	 96		A1	_	2004	1229		WO 2	004-	 IN52			2	0040	304
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MΖ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,
		ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,
		TD,	TG														
IN	1 20031	MU00	647		Α		2005	0211		IN 2	003-1	MU64	7		2	0030	620
US	2006	0270	858		A1		2006	1130		US 2	005-	5539	57		2	0051	019
PRIORIT	Y APP	LN.	INFO	.:						IN 2	003-1	MU64	7		A 2	0030	620
										IN 2	003-1	MU72	1		A 2	0030	717
									,	WO 2	004-	IN52			W 2	0040	304
OTHER S	` ,						CACT 142:93675; MARPAT 142:93675										

The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnC12, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and

the

product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 q wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at $3.5-4.5 \text{ Kg/cm}^2$ at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

72956-09-3P, Carvedilol 95093-99-5P, ΤТ

> (R)-1-(9H-Carbazol-4-yloxy)-3-[[2-[2-(methoxy)phenoxy]ethyl]amino]propan-2-(methoxy)phenoxy]ethyl]amino]propan-2-ol

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)

72956-09-3 HCAPLUS 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-CN (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 95093-99-5 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 95094-00-1 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l10 ibib abs hitstr tot

L10 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:397789 HCAPLUS

DOCUMENT NUMBER: 148:239026

TITLE: A cost effective process for production of

carvedilol

INVENTOR(S): Shankar, Sanganabhatla; Pandurang, Suryavanshi

Jitendra; Moorthy, Koduru Ramanarasimha

PATENT ASSIGNEE(S): Wanbury Limited, India SOURCE: Indian Pat. Appl., 8pp.

CODEN: INXXBO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00771	A	20060825	IN 2006-MU771	20060522
PRIORITY APPLN. INFO.:			IN 2006-MU771	20060522

OTHER SOURCE(S): CASREACT 148:239026

AB A cost effective process for preparation of highly pure carvedilol substantially free from impurities is described herein;

1-[carbazolyl-(4)-oxy]-3-[N-benzyl-2-(2-methoxyphenoxy)-ethylamino]-propan-2-ol is catalytically hydrogenated using inexpensive catalyst like Raney Nickel and isolating crude carvedilol free from penultimate and other major impurity; which is purified in an Et acetate/methyl Et ketone to obtain pure Carvedilol.

IT 72956-09-3P, Carvedilol

RL: SPN (Synthetic preparation); PREP (Preparation) (a cost effective process for production of carvedilol)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L10 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of

1-[9H-carbazol-4-yloxy]-3-[[2-(2-

methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
20041229
                                          WO 2004-IN52
     WO 2004113296
                        A1
                                                                   20040304
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     IN 2003MU00647
                                20050211
                                            IN 2003-MU647
                                                                   20030620
                         Α
     US 20060270858
                         A1
                               20061130
                                            US 2005-553957
                                                                   20051019
PRIORITY APPLN. INFO.:
                                            IN 2003-MU647
                                                               A 20030620
                                            IN 2003-MU721
                                                               A 20030717
                                            WO 2004-IN52
                                                              W 20040304
OTHER SOURCE(S):
                       CASREACT 142:93675; MARPAT 142:93675
```

GT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AΒ The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 q (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrousZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and

the

product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 q wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

72956-09-3P, Carvedilol 95093-99-5P, (R)-1-(9H-Carbazol-4-yloxy)-3-[[2-[2-(methoxy)phenoxy]ethyl]amino]propan-2-(methoxy)phenoxy]ethyl]amino]propan-2-ol

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl) benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 95093-99-5 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 95094-00-1 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:556143 HCAPLUS

DOCUMENT NUMBER: 137:125080

TITLE: Process for preparing heterocyclic indene

analogs by cyclocarbonylation at moderate temperatures

and catalyst loading

INVENTOR(S): Scalone, Michelangelo; Zeibig, Thomas Albert

PATENT ASSIGNEE(S): Hoffmann-LaRoche Inc., Switz. SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```
PATENT NO. KIND DATE APPLICATION NO. DATE
                                             _____
     _____
                         ----
                                                                       _____
     US 20020099223
                         A1 20020725 US 2002-54462
                                                                       20020122
     US 6777559
                          B2 20040817
                         A1 20020801 CA 2002-2434408 20020122
     CA 2434408
     WO 2002059089 A2 20020801
WO 2002059089 A3 20021031
                                             WO 2002-EP583
                                                                      20020122
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002247645 A1 20020806 AU 2002-247645 20020122
EP 1355880 A2 20031029 EP 2002-716673 20020122
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004519465 T 20040702
JP 4056883 B2 20080305
IN 2003CN01126 A 20050422
MX 2003PA06606 A 20030922
US 20040127723 A1 20040701
US 7169935 B2 20070130
                                20040702
                                            JP 2002-559391
                                                                       20020122
                                           IN 2003-CN1126
MX 2003-PA6606
US 2004-763296
                                              IN 2003-CN1126
                                                                       20030722
                                                                       20030723
                                                                       20040122
                                              EP 2001-101584 A 20010125
US 2002-54462 A3 20020122
WO 2002-EP583 W 20020122
PRIORITY APPLN. INFO.:
                     CASREACT 137:125080; MARPAT 137:125080
OTHER SOURCE(S):
     A process for the preparation heterocyclic indene analogs, especially with
```

AB A process for the preparation heterocyclic indene analogs, especially with the preparation of 4-hydroxycarbazole or N-protected 4-hydroxycarbazole, involves cyclocarbonylation followed by saponification This process avoids high temps. and high catalyst loadings.

IT 72956-09-3P, Carvedilol

RL: IMF (Industrial manufacture); PREP (Preparation) (process for preparing heterocyclic indene analogs by cyclocarbonylation at moderate temps. and catalyst loading)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

MeO

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:67254 HCAPLUS

DOCUMENT NUMBER: 130:262077

TITLE: Carvedilol inhibition of lipid peroxidation. A new

antioxidative mechanism

AUTHOR(S): Tadolini, Bruna; Franconi, Flavia

CORPORATE SOURCE: Dipartmento di Scienze Biomediche, Sezione di

Biochimica, Universita di Sassari, Sassari, I-07100,

Italy

SOURCE: Free Radical Research (1998), 29(5), 377-387

CODEN: FRARER; ISSN: 1071-5762

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal LANGUAGE: English

AB To define the mol. mechanism(s) of carvedilol inhibition of lipid peroxidn. we have utilized model systems that allow us to study the

different reactions involved in this complex process. Carvedilol inhibits the peroxidn. of sonicated phosphatidylcholine liposomes triggered by FeCl2 addition whereas atenolol, pindolol and labetalol are ineffective. The inhibition proved not to be ascribable (a) to an effect on Fe2+ autoxidn. and thus on the generation of oxygen derived radical initiators; (b) to the scavenging of the inorg. initiators 0.ovrhdot.2- and .OH; (c) to an effect on the reductive cleavage of organic hydroperoxides by FeCl2; (d) to the scavenging of organic initiators. The observations that (a) carvedilol effectiveness is inversely proportional to the concentration of FeCl2 and lipid hydroperoxides in the assay; (b) the

drug

RN

prevents the onset of lipid peroxidn. stimulated by FeCl3 addition and; (c) it can form a complex with Fe3+, suggest a mol. mechanism for carvedilol action. It may inhibit lipid peroxidn. by binding the Fe3+ generated during the oxidation of Fe2+ by lipid hydroperoxides in the substrate. The lag time that carvedilol introduces in the peroxidative process would correspond to the time taken for carvedilol to be titrated by Fe3+; when the drug is consumed the Fe3+ accumulates to reach the critical parameter that stimulates peroxidn. According to this mol. mechanism the antioxidant potency of carvedilol can be ascribed to its ability to bind a species, Fe3+, that is a catalyst of the process and to its lipophilic nature that concs. it in the membranes where Fe3+ is generated by a site-specific mechanism.

IT 72956-09-3, Carvedilol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(carvedilol inhibition of lipid peroxidn.: new antioxidative mechanism) 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

MeO

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 ibib abs hitstr tot

L12 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of

1-[9H-carbazol-4-yloxy]-3-[[2-(2-

methoxyphenoxy)ethyl]amino]propan-2-ol

Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev; Thennati, Rajamannar INVENTOR(S):

Sun Pharmaceutical Industries Limited, India PATENT ASSIGNEE(S):

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATE	PATENT NO.					D	DATE APPLICATION NO.										
WO 2	WO 2004113296																
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MΖ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,
		ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,
		TD,	TG														
IN 2	20031	00 UP	647		Α		2005	0211		IN 2	003-1	MU64	7		2	0030	620
US 2	2006	0270	858		A1		2006	1130		US 2	005-	5539	57		2	0051	019
PRIORITY	PRIORITY APPLN. INFO.:									IN 2	003-1	MU64	7		A 2	0030	620
										IN 2	003-1	MU72	1		A 2	0030	717
									,	WO 2	004-	IN52		,	W 2	0040	304
OTHER SOU	. ,					REAC	CACT 142:93675; MARPAT 142:93675										

The present invention provides a process for preparation of AB 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol(I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9Hcarbazole were added and the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous

layer was separated, and the product enriched organic layer was washed with water $\ensuremath{\mathsf{water}}$

till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at $3.5-4.5~\rm Kg/cm2$ at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

ΙT

with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g). 72956-09-3P, Carvedilol 95093-99-5P,

(R)-1-(9H-Carbazol-4-ylovy)-3-[[2-[2-(methoxy)phenoxylethyllaminolprop

(methoxy)phenoxy]ethyl]amino]propan-2-ol

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol) (N-benzylcarvedilol)

RN 72956-09-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 95093-99-5 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

RN 95094-00-1 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 115 ibib abs hitstr tot

L15 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:38855 HCAPLUS

DOCUMENT NUMBER: 146:142505

TITLE: Process for preparation of

carvedilol

INVENTOR(S): Kumar, Ashok; Saxena, Ashvini; Bhattacharyya, Anindya;

Singh Sengar, Amit Vikram; Pathak, Gunjan Pramod; Soudagar, Satish Rajanikant; Mathur, Pramil Kumar; Nijasure, Avinash Manohar; Salunke, Sanjukumar Motiram; Gautam, Prashant; Ramsingh, Thakur

Gajendrasingh; Jadhav, Dilip Uttam

PATENT ASSIGNEE(S): IPCA Laboratories Ltd., India

Eur. Pat. Appl., 11pp. SOURCE:

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1741700	A1	20070110	EP 2006-116752	20060706
R: AT, BE, BG,	CH, CY	, CZ, DE,	DK, EE, ES, FI, FR,	GB, GR, HU, IE,
IS, IT, LI,	LT, LU	, LV, MC,	NL, PL, PT, RO, SE,	SI, SK, TR, AL,
BA, HR, MK,	YU			
IN 2005MU00807	A	20070629	IN 2005-MU807	20050706
US 20070027202	A1	20070201	US 2006-480526	20060705
PRIORITY APPLN. INFO.:			IN 2005-MU807	A 20050706

OTHER SOURCE(S): CASREACT 146:142505

Disclosed herein is a process for preparation of carvedilol free from impurity, which comprises reaction of 4-(2,3epoxypropoxy) carbazole with 2-(2-methoxyphenoxy) ethylamine in a polar aprotic solvent, followed by isolation of carvedilol as an acid addition salt and subsequent conversion into pure carvedilol

REFERENCE COUNT: THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

2004:1154673 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 142:93675

A process for preparation of TITLE:

1-[9H-carbazol-4-yloxy]-3-[[2-(2methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.					KIND DAT					APPL	ICAT	ION :	NO.		D.	DATE				
WO	WO 2004113296					_	2004	 1229		 WO 2	004-	 IN52			2	0040	304			
	W:	ΑE,	ΑG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,			
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,			
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,			
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NΙ,			
		NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,			
		ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW			
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,			
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,			
		ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙΤ,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,			
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,			
		TD,	ΤG																	

IN 2003MU00647 A 20050211 IN 2003-MU647 20030620 US 20060270858 A1 20061130 US 2005-553957 20051019 PRIORITY APPLN. INFO.: IN 2003-MU647 A 20030620 IN 2003-MU721 A 20030717 WO 2004-IN52 W 20040304

OTHER SOURCE(S): CASREACT 142:93675; MARPAT 142:93675

GΙ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The present invention provides a process for preparation of AR 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound ${\tt I}$, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to $400~\mathrm{mL}$ EtOAc, $70~\mathrm{g}$ (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and the

product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at $3.5-4.5~{\rm Kg/cm2}$ at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l16 ibib abs hitstr tot

L16 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:38855 HCAPLUS

DOCUMENT NUMBER: 146:142505

TITLE: Process for preparation of

carvedilol

INVENTOR(S): Kumar, Ashok; Saxena, Ashvini; Bhattacharyya, Anindya;

Singh Sengar, Amit Vikram; Pathak, Gunjan Pramod; Soudagar, Satish Rajanikant; Mathur, Pramil Kumar; Nijasure, Avinash Manohar; Salunke, Sanjukumar Motiram; Gautam, Prashant; Ramsingh, Thakur Gajendrasingh; Jadhav, Dilip Uttam

PATENT ASSIGNEE(S): IPCA Laboratories Ltd., India

SOURCE: Eur. Pat. Appl., 11pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	ENT N				KIN	O	DATE		APPLICATION NO.						DATE				
	17417	700					2007	-				_	-						
							CZ, LV,	•	•		,						•		
		BA,																	
IN :	2005™	1U 0 0 8	307		Α		2007	0629		IN 2	005 - 1	MU80	7		2	0050	706		
US :	20070	0272	202		A1		2007	0201		US 2	006-	4805	26		2	0060	705		
PRIORITY	APPL	JN. I	NFO	.:						IN 2	005-1	08UM	7	Ž	A 2	0050	706		
OTHER SO	URCE ((S):			CASI	REAC	T 14	6:14	2505										
	close e fro				-				-										
	xypro otic										noxy) eth	ylam	ine :	in a	pol	ar		
	vedil e car				id a	ddit	ion	salt	and	sub	sequ	ent (conv	ersi	on i	nto			

=> d l18 ibib abs hitstr tot

REFERENCE COUNT:

L18 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:38855 HCAPLUS

DOCUMENT NUMBER: 146:142505

TITLE: Process for preparation of

carvedilol

INVENTOR(S): Kumar, Ashok; Saxena, Ashvini; Bhattacharyya, Anindya;

Singh Sengar, Amit Vikram; Pathak, Gunjan Pramod; Soudagar, Satish Rajanikant; Mathur, Pramil Kumar; Nijasure, Avinash Manohar; Salunke, Sanjukumar Motiram; Gautam, Prashant; Ramsingh, Thakur

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Gajendrasingh; Jadhav, Dilip Uttam

PATENT ASSIGNEE(S): IPCA Laboratories Ltd., India

SOURCE: Eur. Pat. Appl., 11pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
EP 1741700	A1 20070110	EP 2006-116752	20060706			
R: AT, BE, BG,	CH, CY, CZ, DE,	DK, EE, ES, FI, FR, GB	, GR, HU, IE,			
IS, IT, LI,	LT, LU, LV, MC,	NL, PL, PT, RO, SE, SI	, SK, TR, AL,			
BA, HR, MK,	YU					
IN 2005MU00807	A 20070629	IN 2005-MU807	20050706			

US 20070027202 A1 20070201 US 2006-480526 20060705 PRIORITY APPLN. INFO.: IN 2005-MU807 A 20050706

OTHER SOURCE(S): CASREACT 146:142505

AB Disclosed herein is a process for preparation of carvedilol free from impurity, which comprises reaction of 4-(2,3-

epoxypropoxy) carbazole with 2-(2-methoxyphenoxy) ethylamine in a polar

aprotic solvent, followed by isolation of

carvedilol as an acid addition salt and subsequent conversion into

pure carvedilol.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOG Y

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
98.35
277.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -10.40 -10.40

STN INTERNATIONAL LOGOFF AT 13:12:19 ON 24 AUG 2008